Jurie Tashkandi,Robert Brkljača,Marie Zhang et al. Jurie Tashkandi et al.

In a xenograft ovarian cancer mouse model, we achieved significant tumor uptake of the SPION through intravenous delivery and accurately quantified the iron amount both in and ex vivo using MPI and ICP-MS.

Chyi-Long Lee Chyi-Long Lee

Qin Ling,Linxiang Wu,Huishan Xu et al. Qin Ling et al.

Background: While various lifestyle factors have been implicated in cancer prognosis, the role of dietary vitamins in ovarian cancer survival is not well understood....This study aimed to investigate the association between dietary vitamin intake and all-cause mortality in ovarian cancer patients, presenting a potential modifiable avenue for improving outcomes....Methods: Data were obtained from 7 consecutive National Health and Nutrition Examination Survey (NHANES) cycles between 2003 and 2016, including 108 ovarian cancer patients. Mortality outcomes were ascertained by matching the National Death Index (NDI)....Results: A total of 108 ovarian cancer patients were included, of which 24 participants have died. In the adjusted model, higher vitamin A intake was significantly associated with an increased all-cause mortality (HR = 3.826; 95% CI = 1.378-10.627; p = 0.01)....These results highlight the potential for personalized dietary interventions in ovarian cancer management.

Hao Lin,Yu-Che Ou,Hung-Chun Fu et al. Hao Lin et al.

Homologous recombination (HR) status plays a critical role in selecting advanced epithelial ovarian cancer (EOC) patients for poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. This study aimed to develop a novel nomogram to predict prognosis in these patients in the era of precision medicine.

Zheyu Hu,Li Li,Zhe Yang et al. Zheyu Hu et al.

factors such as body mass index (BMI), carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4), International Federation of Gynecology and Obstetrics (FIGO) staging and platinum sensitivity, and pathological characteristics on progression-free survival (PFS) in platinum-sensitive recurrent ovarian...cancer (PSROC) patients treated with niraparib, and to identify independent prognostic factors for treatment outcomes....Methods: A total of 312 patients with ovarian cancer undergoing treatment between Jan. 2020 and Jan. 2022 were selected for the retrospective study.

Yijun Wang,Yicong Wang,Lei Wang et al. Yijun Wang et al.

Objective: To assess the efficacy and safety of bevacizumab in neoadjuvant chemotherapy for ovarian cancer through systematic evaluation and meta-analysis....Methods: Online databases, such as PubMed, Embase, and the Cochrane Library, were searched for relevant articles on the treatment of ovarian cancer patients with interval debulking surgery after neoadjuvant chemotherapy in combination with the bevacizumab regimen using the keywords...Conclusion: The use of bevacizumab in neoadjuvant chemotherapy for advanced ovarian cancer was safe and feasible but did not significantly improve the satisfactory tumor reduction rate of interval debulking surgery and had no effect on the prolongation of postoperative PFS....Hence, the use of bevacizumab in preemptive chemotherapy for ovarian cancer should be carefully considered.

Ali Reza Eftekhari Moghadam,Milad Jalilian,Forouzan Absalan et al. Ali Reza Eftekhari Moghadam et al.

Post-processing of three-dimensional apparent diffusion coefficient (ADC) maps has proven useful in evaluating variable tumors, although its position in ovarian cancer prognosis is until now not well defined.

Yan Zhang,Wei Wang,Lian Xu et al. Yan Zhang et al.

Objective: To investigate the expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in ovarian cancer tissues and its correlation with clinicopathologic features, chemotherapy sensitivity, and prognosis in patients with ovarian cancer....Methods: Paraffin tissue blocks were collected from 227 ovarian cancer patients, and immunohistochemical (IHC) staining was performed to analyze the expression of ROR1....Results: ROR1 expression and tumor load: higher expression of ROR1 was associated with a heavier tumor load in ovarian cancer patients....Conclusion: ROR1 expression may be related to treatment strategy and history of platinum-based chemotherapy in ovarian cancer patients. Targeting ROR1 could represent a promising therapeutic strategy for the treatment of ovarian cancer.

Colin C Young,Ashley Lahr,Caroline Nestor et al. Colin C Young et al.

Pathogenic alterations in BRCA1 are associated with autosomal dominant breast and ovarian cancer and autosomal recessive Fanconi Anemia Subtype S (FA-S). FA-S accounts for A, p.C64Y and c.3991C>T, p.Q1331*) were identified in trans.

Yuan-Yuan Zhang,Qiu-Xia Zeng,Li Wang et al. Yuan-Yuan Zhang et al.

Objective: This study aimed to investigate the antitumor effects of norcantharidin (NCTD) in ovarian cancer and to elucidate its molecular targets and mechanisms of action, with a focus on the methyltransferase-like protein 16 (METTL16)/ methionine adenosyl transferase II alpha (MAT2A...Materials and methods: Expression levels of METTL16 and MAT2A were analyzed in ovarian cancer tissues and cells using immunohistochemistry, quantitative real-time polymerase chain reaction, and western blotting....Human ovarian cancer cell lines (ES2 and SKOV3) were cultured and subjected to METTL16 overexpression via gene recombination. The cytotoxic effects of varying concentrations of NCTD were assessed using the Cell Counting Kit-8 assay....Results: METTL16 and MAT2A gene expression levels were significantly elevated in ovarian cancer tissues and cell lines (p < 0.05). Treatment with NCTD at 10 μg/mL significantly inhibited proliferation and induced apoptosis in ES2 and SKOV3 cells....Conclusions: NCTD exerts antineoplastic effects in ovarian cancer by reducing intracellular S-adenosylmethionine levels, promoting PP2A demethylation, and inhibiting the METTL16/MAT2A signaling pathway.